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Purpose: To explore a prognostic or predictive role of magnetic resonance imaging 
(MRI) and O-(2-18F-fluoroethyl)-L-tyrosine (18FET) positron emission tomography 
(PET) parameters for outcome in the randomized multi-center trial ARTE that 
compared bevacizumab plus radiotherapy with radiotherpay alone in elderly patients 
with glioblastoma. 
 
Experimental Design: Patients with isocitrate dehydrogenase wild-type glioblastoma 
aged 65 years or older were included in this post-hoc analysis. Tumor volumetric and 
apparent diffusion coefficient (ADC) analyses of serial MRI scans from 67 patients 
and serial 18FET-PET tumor-to-brain intensity ratios (TBR) from 31 patients were 
analyzed blinded for treatment arm and outcome. Multivariate Cox regression 
analysis was done to account for established prognostic factors and treatment arm.  
 
Results: Overall survival benefit from  bevacizumab plus radiotherapy compared to 
radiotherapy alone was observed for larger pre-treatment MRI contrast-enhancing 
tumor (hazard ratio [HR] per cm3 0.94, 95% confidence interval [CI] 0.89-0.99) and 
for higher ADC (HR 0.18, CI 0.05-0.66). Higher 18FET-TBR on pre-treatment PET 
scans was associated with inferior overall survival in both arms. Response assessed by 
standard MRI-based RANO criteria was associated with overall survival in the 
bevacizumab plus radiotherapy arm by trend only (p=0.09). High 18FET-TBR of non-
contrast-enhancing tumor portions during bevacizumab therapy was associated with 
inferior overall survival on multivariate analysis (HR 5.97, CI 1.16-30.8). 
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Conclusion: Large pre-treatment contrast-enhancing tumor mass and higher ADC 
identify patients who may experience a survival benefit from bevacizumab plus 
radiotherapy. Persistent 18FET-PET signal of no longer contrast-enhancing tumor 
after concomitant bevacizumab plus radiotherapy suggests pseudoresponse and 
predicts poor outcome. 
 






Response assessment of brain tumor patients exposed to anti-angiogenic therapy 
remains challenging because reduction of contrast enhancement on MRI may reflect 
blood brain barrier restoration rather than tumor regression, a phenomenon termed 
pseudoresponse. The Response Assessment in Neuro-Oncology (RANO) working 
group supports the use of amino acid PET to monitor non-contrast-enhancing tumor 
growth in bevacizumab-treated patients based on limited evidence. We herein report 
the MRI/PET sub-study of a randomized, clinically and molecularly well-annotated 
multi-center cohort of IDH wild-type glioblastoma patients treated with or without 
bevacizumab. Our exploratory analyses suggest that larger pre-treatment contrast-
enhancing tumor volume and low 18FET intensity of non-contrast-enhancing tumor 
during bevacizumab treatment may predict survival benefit from bevacizumab plus 
radiotherapy. MRI response by RANO was only by trend associated with overall 
survival in bevacizumab-treated patients. Our study supports the use of 18FET 
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intensity in non-contrast-enhancing tumor to identify pseudoresponse in glioblastoma 





Glioblastoma is an invariably fatal disease with a median overall survival in the range 
of one year (1). The proliferation of hyperplastic, dysfunctional blood vessels is a 
histological hallmark of glioblastoma (2). Vascular endothelial growth factor A 
(VEGF), a key driver of angiogenesis in glioblastoma and other cancers, can be 
targeted with the VEGF-neutralizing antibody bevacizumab (BEV) (3). Definitive 
FDA approval of BEV for the treatment of recurrent glioblastoma was based on 
prolonged progression-free survival (PFS) and apparent clinical benefit (4-6). 
However, randomized clinical trials of BEV in patients with newly diagnosed or 
recurrent glioblastoma failed to demonstrate prolonged overall survival (6-8). 
 
Pre-treatment magnetic resonance imaging (MRI) parameters, including absence of 
imaging necrosis or higher apparent diffusion coefficients (ADC), may identify 
subgroups of patients with overall survival benefit from BEV in recurrent 
glioblastoma (9-11). How to optimally monitor glioblastoma patients treated with 
BEV remains a matter of debate, because contrast enhancement on T1-weighted MRI 
sequences – the key parameter to monitor glioblastoma growth in classical response 
criteria (12,13) – may decrease within days after implementation of anti-angiogenic 
therapy and often reflects restoration of blood brain barrier function rather than tumor 
shrinkage (14-16). This phenomenon has been termed pseudoresponse (17) and may 
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account for unrecognized disease progression in patients on anti-angiogenic therapy, 
leading to deferred salvage therapy and potentially even shorter overall survival.  
 
The Response Assessment in Neuro-Oncology (RANO) working group has 
incorporated clinical parameters and T2-weighted MRI sequences as measures to 
address the challenges of misleading treatment-induced contrast enhancement 
dynamics (12). There is however large interobserver variability regarding the time-
point of progression by RANO (18) and in BEV-treated patients, response by RANO 
may not predict overall survival in patients with newly diagnosed (19) or recurrent 
glioblastoma (20). 
 
Positron emission tomography (PET) utilizing the amino acid tracers O-(2-18F-
fluoroethyl)-L-tyrosine (18FET) or (S-11C-methyl)-L-methionine (11C-MET) can be 
utilized to differentiate viable glioma tissue from treatment-induced changes with 
high sensitivity and specificity (21). Uncontrolled studies suggest that 18FET-PET 
may detect tumor progression during anti-angiogenic treatment earlier than MRI 
(20,22,23). This led the RANO working group to incorporate recommendations for 
the use of amino acid PET in the response assessment of such patients (24).  
 
The randomized multi-center open label phase II trial ARTE explored the efficacy of 
BEV as an adjunct to hypofractionated radiotherapy (RT) in elderly patients (> 65 
years) with newly diagnosed glioblastoma (25). Here we report associations of serial 
MRI and 18FET-PET parameters with benefit from BEV plus RT in this clinically and 








ARTE was a 2:1 randomized phase II clinical trial of hypofractionated RT of 15 x 
2.66 = 40 Gy in combination with BEV 10 mg/kg bodyweight administered every two 
weeks compared to hypofractionated RT alone in elderly (> 65 years) patients with 
newly diagnosed glioblastoma. Here we analyzed associations of pre-treatment and 
follow-up imaging parameters by treatment arm with outcome. Patients with isocitrate 
dehydrogenase (IDH)-mutant glioblastoma or alternative diagnoses by central 
pathology review were excluded from this analysis. Outcome measures were PFS 
from randomization and overall survival from histological diagnosis. The ARTE trial 
and post-hoc translational analyses were approved by the local ethical committee 
(KEK-ZH No. 2011-0135) and were conducted in accordance with the Declaration of 
Helsinki and its amendments. All patients gave written informed consent prior to 





Analysis of the promoter methylation status of the O6-methylguanine DNA 
methyltransferase (MGMT) promoter region was done in all patients and a methylated 
MGMT promoter became an exclusion criterion by amendment (November 2013) 
when it became clear that patients with tumors with a methylated MGMT derived 
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larger benefit from temozolomide monotherapy than from RT alone (26,27). MGMT 
promoter methylation status was determined by methylation-specific PCR (28). IDH 
mutation status was determined by immunohistochemistry (29) or sequencing of 
IDH1 and IDH2. Genome-wide CpG methylation was determined by 450k array 
profiling and classified utilizing a publically available tool 
(www.molecularneuropathology.org) (30). Genomic copy number alterations were 
derived from methylation arrays and subtypes annotated manually according to 
prognostic subgroups (31). Gene expression subtypes were determined utilizing the 
nCounter gene expression platform (NanoString Technologies, Seattle, WA) to assess 




MRI and 18FET-PET parameters 
 
Pre-treatment MRI and 18FET-PET were performed post-operatively within 10 days 
before the start of study treatment, BEV plus RT or RT alone. Follow-up scans were 
to be acquired 4 weeks after completion of RT (week 7) and at least every three 
months thereafter until progression. MRI was done according to local investigators’ 
protocols on 1.5 T or 3 T scanners. Gadolinium was used as contrast agent. The slice 
thickness was at the most 3 mm for any sequences analyzed. There was no centralized 
specification of echo or repetition times or of field-of-view values. MRI included 
contrast enhancement and T2 as the minimum set of sequences for volumetric 
characterization and response assessment. Pre-treatment necrosis was defined as 
hyperintensity on T2 and hypointensity on T1 located within contrast enhancement. 
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Diffusion-weighted sequences were expressed by mean ADC in absolute units of 10-
3mm2/s. ADCL, the mean of the lower distribution of a double Gaussian model, was 
also determined. Fractional anisotropy was not reported. Pre-treatment contrast-
enhancing and T2 volumes were determined utilizing the Brainlab Elements version 
2.6 software (Brainlab, Munich, Germany). Treatment response for MRI sequences 
was determined according to RANO criteria by measuring perpendicular tumor 
diameters to yield bidimensional tumor size estimates in mm2 and taking the clinical 
course into account (12). Tumor size changes during follow-up were calculated as 
percent change from pre-treatment scans. Static 18FET-PET scans were acquired 30 to 
50 minutes after tracer injection. A standardized imaging acquisition protocol for 
MRI and PET scans was implemented in all centers participating in the ARTE trial. 
 
Both ADC values and 18FET intensity values were also measured separately for non-
enhancing and for enhancing tumor to account for different diffusion properties and 
passive tracer diffusion (34). Diffusion-weighted MRI and PET images were fused 
with contrast-enhancing MRI. Non-contrast-enhancing tumor was defined by T2 
hyperintensity in the absence of contrast enhancement, i.e. including areas of potential 
vasogenic edema. PET region-of-interest (ROI) analysis was done outlining the 
respective tumor compartments on the superimposed MRI and PET images. ROI were 
determined in two perpendicular planes, each in the slice with the maximum tumor 
area. For 18FET intensity quantification, tumor-to-brain ratios (TBR) were determined 
by dividing the mean tumor ROI intensity values on the plane with the largest tumor 
area on MRI by the mean intensity in a ROI on the plane with the largest cerebellar 
diameter as the reference (35). Analyses of imaging parameters were done centrally 






The Chi-square test was applied to compare categorical variables and the Mann-
Whitney-U test was applied for continuous variables. Receiver operator 
characteristics (ROC) curve analyses utilizing median overall survival to determine 
prognostic cutoffs were done to segregate patients by continuously scaled imaging 
parameters. Best response was computed as time-dependent covariate as indicated. 
Treatment arms and indicated subgroups were compared in exploratory analyses with 
respect to progression-free survival and overall survival using the log rank test, or 
univariate and multivariate Cox proportional hazards models incorporating indicated 
covariates. Age and Karnofsky performance score (KPS) were dichotomized at 
established cut-offs (age: 71 years or more versus 65-70 years, KPS: <90% versus 90-
100%) (25). No correction for multiple testing was done in this exploratory analysis. 







The primary analysis population is detailed in Figure 1. Of 75 patients enrolled, 50 
were treated with BEV plus RT and 25 with RT alone. Eight patients were excluded 
from subsequent analyses, two in the BEV plus RT arm with mutated IDH, one 
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patient in each arm with an alternative diagnosis on central pathology review, and 
four patients without pre-treatment MRI available. Longitudinal volumetric analyses 
of contrast-enhanced and T2-weighted MRI sequences were available from 44 and 23 
patients, ADC from 37 and 20 patients, and 18FET-TBR from 19 and 12 patients, in 
the BEV plus RT and RT arms. Demographic, clinical and molecular characteristics 
at baseline were balanced between arms, including age, sex, contrast-enhancing tumor 
volume, Karnofsky performance score (KPS), steroid use, MGMT promoter 
methylation status, genome methylation subtypes and gene expression subtypes in the 
overall cohort (25), and in the sub-cohorts with available MRI and FET-PET studied 
here (Table 1, Table S1). 
 
 
Pre-treatment contrast enhancement and ADC are associated with overall survival 
benefit from BEV plus RT 
 
ROC curve analyses identified a pre-treatment contrast enhancement cutoff at 3.1 cm3 
that was associated with overall survival by trend in the BEV plus RT arm (Fig. 2A) 
and at 5.3 cm3 that segregated patients by overall survival in the RT arm (Fig. 2B). 
Analyzing contrast-enhancing volumes as continuous variable confirmed that larger 
pre-treatment contrast-enhancing volume was associated with inferior overall survival 
in both treatment arms. This association was less pronounced in the BEV plus RT arm 
than in the RT arm, suggesting that a negative association of contrast enhancement 
with overall survival is in part abrogated by BEV. Along the same lines, there was an 
interaction of pre-treatment contrast enhancement with treatment arm indicating 
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preferential benefit from BEV plus RT in tumors with larger contrast-enhancing 
volumes (Fig. 2C).  
 
No associations with overall survival in either treatment arm were identified for pre-
treatment volumetric analyses of T2-weighted images (Fig. S1A-C), or of fluid 
attenuated inversion recovery (FLAIR) sequences (not shown). Similar analyses were 
done utilizing cutoffs of pre-treatment contrast enhancement and T2 volumes with 
respect to progression-free survival, but we identified no interactions with 
progression-free survival benefit from BEV plus RT (Note S1, Fig. S2).  
 
We also explored whether imaging necrosis – an MRI surrogate for tumor hypoxia – 
was associated with overall survival. Necrosis was present in 38 of 67 patients (57%) 
on pre-treatment MRI scans and presence of any necrosis was associated with inferior 
outcome (Fig. S3A), but there was no association with benefit from BEV with respect 
to overall survival (Fig. S3B) or progression-free survival (not shown). 
 
ADC values were analyzed in contrast-enhancing tumor portions and cutoffs to 
segregate patients by high versus low mean ADC values were defined by ROC curve 
analyses. In the BEV plus RT arm, pre-treatment ADC values above 1.19 mm2/s were 
associated with longer overall survival (Fig. 2D), but no such association was 
detected in the RT arm (Fig. 2E). There was a marked interaction of pre-treatment 
ADC with treatment arm indicating preferential overall survival benefit from BEV 
plus RT in tumors with higher ADC (Fig. 2F). A similar interaction of higher ADC 
values in contrast-enhancing tumor portions with preferential benefit from BEV plus 
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RT was also observed with respect to PFS (Fig. S3C). 
 
 
Pre-treatment 18FET intensity in contrast-enhancing tumor tissue is associated with 
inferior overall survival independent of treatment 
 
In contrast-enhancing tumor portions, 18FET may enrich due to passive tracer 
diffusion in addition to active uptake by tumor cells (34), thus requiring the separate 
analysis of 18FET intensities in contrast-enhancing and non-contrast-enhancing tumor 
portions. Applying ROC cutoffs of pre-treatment 18FET intensity in contrast-
enhancing tumor lesions identified a marked association of higher 18FET-TBR with 
inferior overall survival in the BEV plus RT arm (Fig. 2G) and by trend in the RT arm 
(Fig. 2H), but there was no specific overall survival benefit from BEV plus RT among 
patients with high or low 18FET intensity (Fig. 2I). We compared the association of 
pre-treatment contrast-enhancing volume, ADC and 18FET intensity TBR with overall 
survival in a multivariable model that included all three parameters and correction 
variables for study arm interactions of ADC and contrast-enhancing volumes (Table 
S2). In this model, high versus low 18FET intensity was negatively associated with 
overall survival (hazard ratio [HR] 3.54, 95% confidence interval [CI] 1.12-11.16, 
p=0.031), but not contrast-enhancing volumes (p=0.39) or ADC (p=0.79), suggesting 
that pre-treatment 18FET intensity in contrast-enhancing tumor portions may reflect 
prognosis more accurately than MRI-based imaging alone. 
 
In non-contrast-enhancing tumor areas, pre-treatment 18FET intensity TBR were 
similar to normal brain (not shown), suggesting that pre-treatment T2 hyperintensity 
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may comprise mostly vasogenic edema and gliosis rather than metabolically active 
tumor cells. Consequently, no associations with overall survival were identified for 
pre-treatment 18FET intensity in non-contrast-enhancing tumor portions (not shown). 
No associations of 18FET intensity TBR with PFS were identified in contrast-
enhancing or non-contrast-enhancing tumor areas (not shown), suggesting that the 




Imaging response assessment by RANO is only weakly associated with overall 
survival in BEV-treated patients 
 
Anti-angiogenic treatment often induces a reduction in contrast enhancement that may 
occur within days from the initiation of therapy. This phenomenon does not 
necessarily reflect a reduction in tumor burden but rather restoration of blood brain 
barrier function (17). One objective of the RANO criteria was to expand criteria for 
differentiating a definition of imaging response and tumor progression and anti-
angiogenic treatment beyond contrast-enhancing tumor, taking clinical and T2-
weighted MRI parameters into account (12). In the ARTE trial, response by RANO 
computed as time-dependent variable was only by trend associated with longer overall 
survival in the BEV plus RT arm whereas there was a clear segregation by overall 
survival in the RT arm (Fig. 3A,B). Utilizing the percent changes between best 
response and pre-treatment value in contrast-enhancing volume estimates, we 
identified response cutoffs that were associated with overall survival in either 
treatment arm, albeit the segregation by contrast-enhancing response was less 
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pronounced in the BEV plus RT arm (cutoff 55% contrast-enhancing volume 
reduction, median overall survival no response vs response = 9.7 vs 12.9 months, 
time-dependent p=0.023, Fig. S3D) than in the RT arm (cutoff 10% contrast-
enhancing volume reduction, median overall survival no response vs response = 8.9 
vs 14.4 months, time-dependent p=0.003, Fig. S3E). No associations with overall 
survival were observed for percent changes of T2 in either treatment arm (not shown).  
 
 
18FET-TBR of non-contrast-enhancing lesions is associated with overall survival in 
BEV-treated patients 
 
18FET-PET was implemented in the ARTE trial to enable detection and monitoring of 
non-contrast-enhancing tumor burden in areas where anti-angiogenic therapy has led 
to a tightened blood-brain barrier that prohibits contrast diffusion. Passive tracer 
diffusion into contrast-enhancing tumor portions (34) implies that the analysis of a 
metabolic response in either compartment is challenged by effects of BEV on the 
spatial contrast-enhancing distribution. Comparing 18FET-TBR of non-contrast-
enhancing tumor portions to the identical tumor region that was contrast-enhancing 
before BEV exposure will likely measure a decreased 18FET intensity that may not 
reflect tumor cell death. As a surrogate for tumor burden and metabolic response to 
treatment in each compartment, we annotated 18FET-TBR from first follow-up after 
RT (week 7) until progression in each patient. In patients with decreasing 18FET-TBR 
at any time during follow-up, we utilized the lowest recorded follow-up value and in 
patients with increasing 18FET-TBR, we utilized the highest recorded value to define 
a high versus low 18FET-TBR cutoff by ROC curve analysis. In the BEV plus RT 
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arm, high 18FET-TBR in non-contrast-enhancing tumor portions during follow-up 
after RT was associated with inferior overall survival by trend (Fig. 3C), but no such 
association was identified in the RT arm (Fig. 3D). Vice versa, high 18FET-TBR in 
contrast-enhancing tumor portions during follow-up after RT was associated with 
overall survival in the RT arm only (Fig. S4). An example of contrast enhancement, 
T2 and utilizing 18FET PET is provided in Fig. 3E. 
 
 
Imaging response by molecular subtypes 
 
We also explored whether distinctive molecular glioblastoma subtypes defined by 
gene methylation, gene expression or genomic copy number alterations were enriched 
for response by RANO criteria or for high or low 18FET-TBR in non-contrast-
enhancing tumor during BEV therapy. No such association was identified for 
complete or partial response versus stable disease or no response by RANO (not 
shown) and likewise, no association of high or low 18FET-TBR in non-contrast-
enhancing tumor was identified with gene methylation (p=0.38), gene expression 





We sought to also explore imaging parameters associated with benefit from BEV in a 
multivariate Cox regression model of overall survival that takes established 
prognostic factors into account, including age, KPS and steroid intake. Univariate 
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associations of these parameters with overall survival are summarized in Table S3. 
Pre-treatment contrast-enhancing tumor and ADC were both associated with overall 
survival (Table 2). We also identified an association of ADCL with overall survival in 
this model (ADCL HR per 0.1 mm/s
2 = 1.59, 95% CI 1.04-2.43, p=0.033). Follow-up 
imaging parameters at the first study visit after RT (week 7) were explored in this 
multivariate model as a clinically relevant paradigm of treatment reevaluation. There 
was a weak association of a decrease in contrast-enhancing tumor mass with 
improved overall survival. High non-contrast-enhancing 18FET intensities on a single 
scan at first follow-up was associated with markedly inferior overall survival, 
suggesting that pseudoresponse was a negative predictor of overall survival. MGMT 
promotor methylation status was not associated with overall survival on univariate or 
multivariate analyses and had no relevant effect on HR determined for ADC or 18FET 





The present secondary analyses of the randomized ARTE trial explored MRI- and 
PET-based parameters for selection and monitoring of patients with newly diagnosed 
IDH wild-type glioblastoma during BEV therapy.  
 
Pre-treatment MRI parameters including contrast-enhancing tumor and ADC, but not 
T2 volumes stratified BEV plus RT-treated patients by overall survival and were 
associated with specific benefit from BEV plus RT compared to RT alone. There was 
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also a strong association of pre-treatment 18FET intensities in contrast-enhancing 
tumor with overall survival, but this was not specific for the BEV plus RT arm. 
 
The interaction of larger pre-treatment contrast-enhancing volume with preferential 
overall survival benefit from BEV plus RT is supported by a less pronounced 
association of pre-treatment tumor size with overall survival in the BEV plus RT arm 
than in the RT arm. Similar results by trend have also been reported from the phase III 
AVAglio trial of BEV in combination with chemoradiotherapy versus 
chemoradiotherapy alone in newly diagnosed glioblastoma (36). Other factors such as 
temozolomide treatment and MGMT promoter methylation status may have been 
more important prognostic factors in AVAglio than in ARTE.  
 
Extent of resection was not determined in the ARTE cohort. However, a relevant 
association of smaller post-operative contrast-enhanced tumor volume with longer 
overall survival was noted in both treatment arms, supporting maximum safe 
resection as the standard of care irrespective of whether or not BEV is administered 
(37). 
 
The phase III European Organization for Research and Treatment of Cancer 
(EORTC) 26101 trial assessed the efficacy of BEV in combination with lomustine in 
recurrent glioblastoma (6). Our study expands on post-hoc analyses of this trial in the 
newly diagnosed setting by confirming an association of baseline imaging necrosis 
with inferior overall survival (11). A dynamic increase of imaging necrosis during 
treatment was observed in a small proportion of patients in EORTC 26101 and, 
irrespective of treatment (11). Similar analyses of outcome by dynamics of necrosis 
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were not feasible in the ARTE study due to the relatively smaller sample size. In the 
EORTC 26101 cohort, presence of necrosis also predicted inferior survival of the 
BEV plus lomustine arm compared with the lomustine alone arm (11), but a similar 
association of BEV plus RT was not noted in the ARTE cohort. 
 
Our study also supports retrospective studies and reports from uncontrolled clinical 
trials in recurrent glioblastoma that proposed ADC as a prognostic parameter in 
patients treated with BEV (9,10,38). As a potential limitation and in contrast to these 
previous studies, we have however used mean ADC and not a double Gaussian mixed 
model for most analyses. Nonetheless, the randomized design of our study supports 
that ADC may be predictive of benefit from bevacizumab rather than a treatment-
agnostic prognostic factor. 
 
The rationale for the use of amino acid PET in patients treated with BEV is to identify 
and monitor viable non-contrast-enhancing tumor portions to account for a commonly 
observed reduction of contrast enhancement that does not necessarily reflect tumor 
cell death (17,24). The clinical utility of this rationale was supported by a strong 
negative association of non-contrast-enhancing 18FET intensity with overall survival 
specifically in patients treated with BEV plus RT. This association was confirmed on 
multivariate analyses at first follow-up after radiotherapy, suggesting that amino acid 
PET may serve as an early marker of pseudoresponse and as a predictor of overall 
survival benefit during BEV plus RT treatment. By contrast, the similar 18FET 
intensity of normal brain and non-contrast-enhancing tumor before treatment or post-
RT in the RT arm suggest that the majority of hyperintensity on T2-weighted MRI 
represents vasogenic edema. Our findings support the proposal by the RANO working 
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group to utilize amino acid PET to monitor tumor growth in BEV-treated 
glioblastoma patients and complements feasibility studies that have indicated better 
accuracy of amino acid PET for disease monitoring than conventional MRI in BEV-
treated glioma patients (20,22,39-42). However, the small sample size of the PET 
cohort warrants further validation of amino acid PET as a predictor of overall survival 
during anti-angiogenic therapy. 
 
The lack of overall survival association of T2 pre-treatment volumes or dynamics in 
either treatment arm of ARTE is of note given that part of the rationale to include a 
T2-based definition of progression in the RANO criteria was to account for 
pseudoresponse to anti-angiogenic therapy (12). Our findings underscore that 
dynamics of T2 hyperintensity do not generally reflect the disease course, but require 
careful evaluation in the context of clinical assessments and treatment. For example, a 
T2 “response” may simply reflect regression of edema in response to BEV, and vice 
versa T2 “progression” may reflect an increase of edema when steroids are weaned, 
or delayed radiation effects. Along the same lines, response defined by the contrast 
enhancement- and T2-based RANO criteria were only weakly associated with overall 
survival in this study and in AVAglio (19). 
 
The lack of overall survival benefit in phase III clinical trials of BEV in combination 
with standard treatments in newly diagnosed (7,8) and recurrent glioblastoma (6) may 
be considered at odds with reports of imaging biomarkers that have been proposed to 
identify patients with presumed overall survival benefit from BEV. If subgroups of 
patients derive overall survival benefit, other subgroups will experience harm from 
BEV when the net outcome is neutral.  
 21 
 
A possible interpretation may be that the herein reported association of higher 18FET-
TBR in non-contrast-enhancing tumor portions with inferior overall survival reflects 
delayed diagnosis of progression and thus deferred salvage therapy. The considerably 
smaller proportion of patients in the BEV plus RT arm compared to the RT arm who 
received any salvage treatment in ARTE (first salvage therapy 25/50 = 50% versus 
18/25 = 72%, second salvage therapy 7/50 = 14% versus 14/25 = 56%) (25) supports 
this explanation. Along the same lines, interobserver bias with respect to the diagnosis 
of progression by RANO criteria has been reported from several clinical trials with 
central radiology review, including ARTE (25) and EORTC 26101 (6,18). Albeit not 
statistically amenable, differences in assessment and outcome between the two phase 
III clinical trials of BEV in newly diagnosed glioblastoma also support the notion that 
deferred diagnosis of progression may negatively impact overall survival in patients 
treated with BEV. The contrast enhancement-based Macdonald criteria (13) in the 
RTOG 0825 trial and the RANO criteria (12) in the AVAglio trial conveyed HRs for 
BEV of 1.12 and 0.88, respectively (7,8). However, the fact that the vast majority of 
patients in the ARTE trial had an unmethylated MGMT promoter questions whether 
the limited efficacy of temozolomide or lomustine in a recurrent setting would have 
yielded a clinically relevant difference in overall survival.  
 
Strengths of our study include the thorough annotation of clinical, molecular and 
imaging parameters. The statistical power was likely further enhanced by the 
inclusion of only elderly patients, because this patient population is deemed to 
preferentially benefit from BEV in combination with different chemotherapy 
regimens based on early uncontrolled trials (5,43,44). Moreover, confounding factors 
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were reduced by exclusion of patients with IDH mutated glioblastoma, which was 
defined as a distinct entity in the current World Health Organization (WHO) 
classification of primary brain tumors based on molecular and clinical features 
distinct from the majority of glioblastomas that lack IDH mutations (2). Other poor 
prognostic characteristics of the ARTE cohort include the lack of MGMT promoter 
methylation in the large majority of patients, because patients with methylated MGMT 
promoter were excluded from ARTE by amendment when it became clear that these 
patients would derive more benefit from temozolomide than from RT (37). That 
MGMT promoter methylation was not prognostic in the ARTE trial is explained by 
the fact that the patients did not receive first-line temozolomide and that only few 
patients received alkylating chemotherapy at recurrence. 
 
Limitations of the analysis include its relatively small sample size, particularly in the 
PET cohort. Although the ARTE trial was designed to include a poor prognosis 
population – i.e. elderly patients with unmethylated MGMT – the median overall 
survival of approximately 12 months is considerably longer than expected based on 
epidemiological studies (1,45). Reasons for this apparent selection of patients with 
better prognostic traits include that patients were required to be able to travel every 
other week to receive bevacizumab infusions. The optional participation in the PET 
study of the ARTE trial required additional traveling and may have aggravated the 
selection towards patients in a better clinical condition. However, patient 
characteristics and overall survival were similar in the MRI and PET cohorts, thus 
arguing against relevant selection bias between these groups. 
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Another limitation of our study is that BEV is not commonly used in the newly 
diagnosed setting of the ARTE trial, but mostly at recurrence of glioblastoma. Beyond 
amino acid PET, the dramatic progress and clinical implementation of advanced MRI 
technologies warrants the expansion of multimodal imaging for monitoring of 
glioblastomas, e.g. by MR spectroscopy (46) or perfusion imaging (47). Lastly, the 
clinical feasibility of machine learning algorithms to define response and progression 
has been demonstrated in the context of BEV therapy of glioblastoma (18,48), 
supporting that unbiased approaches may aid in integrating large amounts of data 
from multimodal imaging in future studies.  
 
In summary, we provide a comprehensive validation of current imaging standards and 
propose improvements in the context of BEV treatment of glioblastoma. Our study 
falsifies T2 as a relevant marker of tumor growth during BEV treatment and does not 
unambiguously support patient selection for BEV treatment based on higher ADC, 
but supports the preferential use of BEV in patients with larger contrast-enhancing 
volumes, and the use of amino acid PET to monitor anti-angiogenic treatment (24). 
Future studies applying these and other parameters prospectively are warranted to 
improve patient selection and disease monitoring in patients treated with BEV, 
particularly in the recurrent setting for which BEV has obtained clinical approval in 
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Table 1. Patient characteristics at baseline. 






Age, years    
  Median 







Sex, N (%)    
  Male 25 (57) 11 (48)  
  Female  19 (43) 12 (52) 0.48 
Tumor volume, cm3 *    
  Median 3.5 1.1  
  Range 0.0-54.1 0.5-40.0 0.35 
KPS, N (%)    
  90-100 22 (50) 15 (65)  
  70-80 







Steroids, N (%) 
  Yes 










  No data 1 0  
MGMT promoter, N (%) 
  Methylated 










  No data 2 1  
Gene methylation class, N (%) 
  Receptor tyrosine kinase I 
  Receptor tyrosine kinase II 
  Mesenchymal 
















  No data 9 5  
Gene expression subtype, N (%) 
  Proneural 
  Classical  













  No data 12 7  
* defined as contrast-enhancing lesions on T1-weighted images; Abbreviations: CL, classical; 
KPS, Karnofsky performance score.  
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Table 2. Multivariate analysis of predictors of inferior overall survival. 
 HR and 95% CI p 
Model   
Study arm: BEV plus RT vs. RT 0.78 (0.44-1.37) 0.39 
Age: 65-70 years vs. >70 years 0.46 (0.27-0.78) 0.004 
KPS: 90-100% vs. 60-80% 0.62 (0.35-1.09) 0.098 
Steroids at study entry: no vs. yes 0.86 (0.56-1.42) 0.56 
   
Imaging parameters*   
Baseline   
contrast enhancement (per cm3) 1.07 (1.01-1.13) 0.017 
ADC (per 0.1 mm/s2) 1.43 (1.04-1.98) 0.030 
   
First follow-up (post-RT, Week 7)   
contrast enhancement (per 10% response) 0.97 (0.95-0.99) 0.021 
18FET intensity in non-contrast-enhancing tumor portions 





* adjusted for interaction with study arm and tested as additional single variables; +cutoffs 









Figure 1. Study population. Abbreviations: ADC, apparent diffusion coefficients; 
BEV plus RT, bevacizumab in combination with hypofractionated radiotherapy; CE, 
contrast enhancement on T1-weighted MRI sequences; 18FET-PET, O-(2-18F-
fluoroethyl)-L-tyrosine positron emission tomography; IDH, isocitrate 
dehydrogenase; MRI, magnetic resonance imaging; RANO, response assessment in 
neuro-oncology working group criteria; RT, radiotherapy alone. 
 
Figure 2. Overall survival by pre-treatment MRI parameters. Overall survival 
was analyzed by contrast-enhancing volumes (CE-T1) (A-C), ADC values (D-F) and 
18FET intensity (G-I). Cutoffs for Kaplan Meier curves were determined by ROC 
curve analyses and depict patients in the BEV plus RT arm (A, D, G) and in the RT 
arm (B, E, H). Hazard ratios of indicated imaging parameters were determined for the 
entire cohort, interaction testing with treatment (interact BEV) and treatment arms 
utilizing the Cox proportional hazards method (C, F, I). Contrast-enhancing tumor 
volume was analyzed as continuously scaled variable depicting the hazard per cm3, 
ADC and 18FET intensity values were dichotomized by ROC cutoffs. 
 
Figure 3. Overall survival by MRI and PET response. A, B, Overall survival by 
best response classified as response versus no response at any timepoint until 
progression determined by the RANO criteria in the BEV plus RT arm (A) and in the 
RT alone arm (B). C, D, Overall survival by best metabolic response classified as 
high versus low 18FET-TBR of non-contrast-enhancing tumor portions at any 
timepoint post treatment until progression in the BEV plus RT arm (C) and in the RT 
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alone arm (D); 18FET-TBR cut-offs were determined by ROC curve analysis; overall 
survival of patients with high versus low 18FET-TBR was compared by the Cox 
proportional hazards method computing best response as a time-dependent variable. 
E, example of indicated imaging parameters before treatment and at progression; 
18FET-PET confirms tumor progression within non-CE-T1, T2 hyperintense regions; 
CE-T1, contrast enhancement on T1-weighted MRI sequences. 
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Note S1 – Associations of pre-treatment parameters with progression-free 
survival 
 
Larger contrast-enhancing tumor volume was associated with shorter progression-
free survival in the BEV plus RT arm (median progression-free survival CE-T1 high 
vs. low = 6.4 vs. 8.6 months, log rank p=0.034, Fig. S2A), but not in the RT arm 
(median progression-free survival CE-T1 high vs. low = 5.4 vs. 5.8 months, p=0.47, 
Fig. S2B). Utilizing univariate Cox regression to also explore CE-T1 tumor volumes 
as continuous variable yielded similar results, but identified no prognostic interaction 
with bevacizumab (Fig. S2C). Similarly, larger pre-treatment T2 volumes were 
associated with shorter progression-free survival in the BEV plus RT arm (median 
progression-free survival T2 high vs. low = 6.1 vs. 8.6 months, log rank p=0.003, Fig. 
S2D), but not in the RT arm (median progression-free survival T2 high vs. low = 4.2 
vs. 5.6 months, p=0.72, Fig. S2E) and likewise no interaction with bevacizumab was 







Figure S1. Overall survival by pre-treatment T2-weighted MRI volumes. A, B, Cutoffs for 
Kaplan Meier curves were determined by receiver operator characteristics (ROC) curve 
analyses in the BEV plus RT arm (A) and in the RT arm (B). C, Hazard ratios were 
determined for the entire cohort, interaction testing with treatment (interact BEV) and 
treatment subgroups utilizing the Cox proportional hazards method. T2 was analyzed as 






Figure S2. Progression-free survival by pre-treatment MRI parameters. progression-free 
survival was analyzed by CE-T1 volumes (A-C) and by T2 volumes (D-F). Cutoffs for Kaplan 
Meier curves were determined by receiver operator characteristics (ROC) curve analyses 
and depict patients in the BEV plus RT arm (A, D) and in the RT arm (B, E). Hazard ratios of 
indicated continuously scaled imaging parameters were determined for the entire cohort, 
interaction testing with treatment (interact BEV) and treatment subgroups utilizing the Cox 





Figure S3. Associations of pre-treatment and response parameters with progression-
free survival and overall survival. A, overall survival of the entire study cohort stratified by 
presence or absence of necrosis on T1 weighted sequences of pre-treatment MRI scans. B, 
Hazard ratios of continuously scaled pre-treatment necrosis volumes on T1 weighted MRI 
sequences were determined with respect to overall survival for the entire cohort, interaction 




hazards method and are expressed as hazard ratio per cm3. C, Hazard ratios of high versus 
low ADC values were determined with respect to progression-free survival for the entire 
cohort, interaction testing with treatment (interact BEV) and treatment subgroups utilizing the 
Cox proportional hazards method. ADC values were dichotomized by ROC curve analysis. 
D, E, overall survival by best contrast enhancement response classified as response versus 
no response at any timepoint until progression in the BEV plus RT arm (D) and in the RT arm 
(E). Percent response cutoffs were determined by receiver operator characteristics curve 
analyses and were compared by the Cox proportional hazards method computing best 








Figure S4. Overall survival by 18FET intensity of CE-T1 tumor portions during 
treatment. Overall survival was analyzed in the BEV plus RT arm (A) and in the RT arm (B). 
Cutoffs in each treatment arm were determined by ROC curve analyses of 18FET tumor-to-
brain intensity ratios from first follow-up after RT (week 7) until progression utilizing the 
lowest recorded value in patients with decreasing post-RT 18FET TBR and the highest value 
in patients with increasing values. For survival analyses, group assignments were computed 
as time-dependent variables. 
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Table S1. Patient characteristics of the ADC and FET-PET cohorts. 
 
 ADC cohort 
N=57 
 


















Age at diagnosis, years       
  Median 70 70  70 69  
  Range 65-83 65-77 0.93 65-87 66-74 0.80 
Gender, N (%)       
  Male 25 (68) 12 (60)     
  Female 12 (32) 8 (40) 0.57    
Tumor volume at study entry, cm3       
  Median 2.9 1.7  3.3 2.2  
  Range 0.0-54.1 0.5-25.4 0.54 0.0-54.1 0.5-
25.4 
0.70 
KPS at study  
entry, N (%) 
      
  90-100 17 (46) 12 (60)  11 (58) 4 (33)  
  70-80 













Steroids at  
study entry, N (%) 
  Yes 

























  No data 1 0  0 0  
MGMT promoter status, N (%) 
  Methylated 

























  No data 1 0  0 0  
Gene methylation subtype, N (%) 
  Receptor Tyrosine  
  Kinase I 
  Receptor Tyrosine  
  Kinase II 
  Mesenchymal 
  Oncogene MYCN-  



















































  No data 6 5  4 2  
Gene expression subtype, N (%) 
  Proneural 
  Classical  



































Table S2. Multivariable analysis of associations of pre-treatment imaging 
parameters with overall survival. 
 HR (95% CI) p 
Contrast enhancement (per cm3) * 1.05 (0.95-1.16) 0.79 
ADC in contrast-enhancing tumor portion:  
high versus low * 
1.27 (0.22-7.32) 0.39 
18FET TBR in contrast-enhancing tumor 
portion: high versus low 
3.54 (1.12-11.16) 0.032 
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Table S3. Univariate analysis of associations with overall survival of variables 
analyzed in the multivariate model in Table 2.  
 
 HR and 95% CI p 
Study arm: BEV plus RT vs. RT 1.08 (0.65-1.78) 0.77 
Age: 65-70 years vs. >70 years 0.51 (0.31-0.82) 0.006 
KPS: 90-100% vs. 60-80% 0.46 (0.27-0.78) 0.004 
Steroids at study entry: no vs. yes 0.63 (0.39-1.02) 0.059 
 



